Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study
- Wang, Lisa
- Heckman, Michael G.
- Aasly, Jan O.
- Annesi, Grazia
- Bozi, Maria
- Chung, Sun Ju
- Clarke, Carl
- Crosiers, David
- Eckstein, Gertrud
- Garraux, Gaetan
- Hadjigeorgiou, Georgios M.
- Hattori, Nobu
- Jeon, Beom
- Kim, Yun J.
- Kubo, Masato
- Lesage, Suzanne
- Lin, Juei Jueng
- Lynch, Timothy
- Lichtner, Peter
- Mellick, George D.
- Mok, Vincent
- Morrison, Karin
- Quattrone, Aldo
- Satake, Wataru
- Silburn, Peter A.
- Stefanis, Leonidas
- Stockton, Joanne D.
- Tan, Eng King
- Toda, Tatsushi
- Brice, Alexis
- Van Broeckhoven, Christine
- Uitti, Ryan J.
- Wirdefeldt, Karin
- Wszolek, Zbigniew
- Xiromerisiou, Georgia
- Maraganore, Demetrius M.
- Gasser, Thomas
- Krüger, Rejko
- Farrer, Matthew J.
- Ross, Owen A.
- Sharma, Manu
DOIAbstract
A recent study MacLeod et al. has shown that an interaction between variants at the LRRK2 and PARK16 loci influences risk of development of Parkinson's disease (PD). Our study examines the proposed interaction between LRRK2 and PARK16 variants in modifying PD risk using a large multicenter series of PD patients (7715) and controls (8261) from sites participating in the Genetic Epidemiology of Parkinson's Disease Consortium. Our data does not support a strong direct interaction between LRRK2 and PARK16 variants; however, given the role of retromer and lysosomal pathways in PD, further studies are warrante
Add to ORKG